Vor Bio highlights telitacicept BAFF/APRIL inhibitor as lead program in B cell-driven autoimmune diseases

• Vor Biopharma outlined its BAFF/APRIL inhibitor telitacicept strategy to treat B cell-driven autoimmune diseases.
• Global Phase 3 enrollment completed in generalized myasthenia gravis; topline data expected in 1H27.
• Ocular myasthenia gravis Phase 3 first patient dosed expected in 1H27; primary Sjögren's disease Phase 3 enrollment ongoing.
• Cash position of about $515 million; runway projected into early 2029.
• China Phase 3 gMG study showed 4.8-point MG-ADL separation versus placebo at week 24; 6.4-point QMG separation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.